Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Tuberous sclerosis complex inactivation disrupts melanogenesis via mTORC1 activation
Juxiang Cao, … , Hans R. Widlund, David J. Kwiatkowski
Juxiang Cao, … , Hans R. Widlund, David J. Kwiatkowski
Published December 5, 2016
Citation Information: J Clin Invest. 2017;127(1):349-364. https://doi.org/10.1172/JCI84262.
View: Text | PDF
Research Article Dermatology Genetics

Tuberous sclerosis complex inactivation disrupts melanogenesis via mTORC1 activation

  • Text
  • PDF
Abstract

Tuberous sclerosis complex (TSC) is an autosomal dominant tumor-suppressor gene syndrome caused by inactivating mutations in either TSC1 or TSC2, and the TSC protein complex is an essential regulator of mTOR complex 1 (mTORC1). Patients with TSC develop hypomelanotic macules (white spots), but the molecular mechanisms underlying their formation are not fully characterized. Using human primary melanocytes and a highly pigmented melanoma cell line, we demonstrate that reduced expression of either TSC1 or TSC2 causes reduced pigmentation through mTORC1 activation, which results in hyperactivation of glycogen synthase kinase 3β (GSK3β), followed by phosphorylation of and loss of β-catenin from the nucleus, thereby reducing expression of microphthalmia-associated transcription factor (MITF), and subsequent reductions in tyrosinase and other genes required for melanogenesis. Genetic suppression or pharmacological inhibition of this signaling cascade at multiple levels restored pigmentation. Importantly, primary melanocytes isolated from hypomelanotic macules from 6 patients with TSC all exhibited reduced TSC2 protein expression, and 1 culture showed biallelic mutation in TSC2, one of which was germline and the second acquired in the melanocytes of the hypomelanotic macule. These findings indicate that the TSC/mTORC1/AKT/GSK3β/β-catenin/MITF axis plays a central role in regulating melanogenesis. Interventions that enhance or diminish mTORC1 activity or other nodes in this pathway in melanocytes could potentially modulate pigment production.

Authors

Juxiang Cao, Magdalena E. Tyburczy, Joel Moss, Thomas N. Darling, Hans R. Widlund, David J. Kwiatkowski

×

Figure 1

Disruption of the TSC protein complex induces loss of pigmentation in melanocytes.

Options: View larger image (or click on image) Download as PowerPoint
Disruption of the TSC protein complex induces loss of pigmentation in me...
(A–D) Highly pigmented iHPMs were infected with lentiviruses expressing TSC1 shRNA or scrambled control (Scr) shRNA and selected with puromycin. (A) Immunoblot analysis shows that TSC1 depletion led to reduced MITF-M and its downstream targets PGC-1α and TYR, as well as mTORC1 activation. (B) Cell pellets from TSC1-depleted cells had reduced pigmentation. (C and D) TSC1-depleted cells had reduced melanin and TYR activity. (E–H) Entirely similar to the data shown in A–D, except that TSC2 shRNAs were expressed. (I–L) TSC2-depleted iHPMs were reconstituted with lentiviruses containing WT TSC2 or patient-derived TSC2-mutant (P419S) or empty vector control viruses (EV) and selected with puromycin. (I) Immunoblot analysis shows that WT TSC2, but not the TSC2 mutant, rescued mTORC1 activation, MITF and PGC-1α expression, and TYR protein levels. (J) Pigmentation, (K) melanin content, and (L) TYR activity were also all rescued by WT TSC2. Data in C, D, G, H, K, L, and M represent the mean ± SD from at least 3 independent experiments. *P < 0.05, by 2-tailed Student’s t test. (M) Expression of the indicated genes was measured by qPCR in control or shRNA-expressing cells. GAPDH was used as a control. (N) Immunoblot analysis of lysates from TSC1- or TSC2-depleted cells treated with MG132 (25 μM) for 6 hours. MITF, PGC-1α, and TYR were not rescued by MG132 treatment. (O and P) TSC1- or TSC2-depleted cells were infected with lentiviruses containing MITF-M or empty vector control (Scr) and selected with puromycin. (O) Immunoblot analysis shows increased MITF and TYR expression in cells infected with MTIF-M lentivirus. (P) Ectopic expression of MITF rescued the pigmentation loss in TSC1- and TSC2-depleted cells. The immunoblots presented in the figure panels include replicate samples run on parallel gels.

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts